STRESSEconomicGlobal
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
Published:
News summary
The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. Investigational New Drug application planned for submission to the U.S.
- Importance
- Low · 23/100
- Impact direction
- Uncertain